EUVIMEDEUVIMED entdecken
Crossref

Early de‐escalation of broad‐spectrum antibiotic therapy in febrile neutropenia

Alyssa Pradhan iD, Annmarie Bosco, Justin Beardsley, Wei-Yuen Su

Internal Medicine Journal · 2026

DOI: 10.1111/imj.70330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Alyssa Pradhan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Prince of Wales Hospital, Randwick, New South Wales, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Febrile Neutropenia, Antimicrobial Stewardship. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims To assess the effectiveness of an antimicrobial stewardship (AMS) intervention in haematology patients with febrile neutropenia (FN) on days of therapy (DOT) of empiric broad‐spectrum antibiotic therapy (EBAT).

Methods

A single‐centre, prospective cohort study of adult haematology patients admitted with FN from 1 May to 30 November 2022, compared with a retrospective cohort of patients admitted from 1 January 2018 to 31 December 2021. AMS intervention involved infectious diseases advice at weekly haematology meetings to encourage cessation of EBAT for patients with FN who were clinically stable with no isolated source. Primary outcome was duration and agent of EBAT DOT for patients without an identifiable source of fever.

Findings

For FN without an identifiable infective source, mean DOT was significantly shorter (7.1 vs 5.0 days ( P = 0.04)). There was also a significant increase in the number of patients for whom EBAT was ceased prior to neutrophil recovery in the prospective cohort (40% vs 61%, P = 0.016). For patients without an identified source, duration of piperacillin‐tazobactam and meropenem therapy decreased from 2018–2021 to 2022, with a trend towards significance (6.1 vs 4.4, P = 0.07; 12.7 vs 4.4, P = 0.07 respectively). There was no increase in recurrence of fever, antibiotic escalation, intensive care unit admission or death within 30 days in the post‐intervention group.

Interpretation

We demonstrate that an AMS intervention decreased EBAT duration for patients without a source of infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsFebrile NeutropeniaAntimicrobial StewardshipHumansFemaleMaleProspective StudiesMiddle AgedRetrospective StudiesAgedAdultPiperacillin, Tazobactam Drug CombinationCohort Studies

Stichwörter der Autor:innen

antimicrobial stewardshipfebrile neutropeniaimmunocompromised hosts

Substanzen

Anti-Bacterial AgentsPiperacillin, Tazobactam Drug Combination

Autor:innen und Institutionen

  • Department of Infectious Diseases, Prince of Wales Hospital, Randwick, New South Wales, Australia.
  • Department of Infectious Diseases, Westmead Hospital, Westmead, New South Wales, Australia.
  • Sydney Infectious Diseases Institute and Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
  • Department of Haematology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
  • University of New South Wales, Sydney, New South Wales, Australia.

ORCID-Profile: Alyssa Pradhan

Zitieren

APA

Pradhan, A., Bosco, A., Beardsley, J., & Su, W. Y. (2026). Early de‐escalation of broad‐spectrum antibiotic therapy in febrile neutropenia. Internal Medicine Journal. https://doi.org/10.1111/imj.70330

Vancouver

Pradhan A, Bosco A, Beardsley J, Su WY. Early de‐escalation of broad‐spectrum antibiotic therapy in febrile neutropenia. Internal Medicine Journal. 2026. doi:10.1111/imj.70330

BibTeX
@article{Pradhan2026,
  author = {Pradhan, Alyssa and Bosco, Annmarie and Beardsley, Justin and Su, Wei-Yuen},
  title = {Early de‐escalation of broad‐spectrum antibiotic therapy in febrile neutropenia},
  journal = {Internal Medicine Journal},
  year = {2026},
  doi = {10.1111/imj.70330}
}
Kostenlos starten →